Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

682710.pdf (502.56 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2018-04-10

Llicència de publicació

cc-by (c) Sahlholm, Kristoffer et al., 2018
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/148123

Pridopidine Reverses Phencyclidine-Induced Memory Impairment

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3389/fphar.2018.00338

Resum

Pridopidine is in clinical trials for Huntington's diseasetreatment. Originally developedas a dopamine D2receptor (D2R) ligand, pridopidine displays about 100-fold higheraffinity for the sigma-1 receptor (sigma-1R). Interestingly, pridopidine slows diseaseprogression and improves motor function in Huntington's disease model mice and,in preliminarily reports, Huntington's disease patients.The present study examinedthe anti-amnesic potential of pridopidine. Thus, memory impairment was produced inmice by administration of phencyclidine (PCP, 10 mg/kg/day) for 10 days, followedby 14 days' treatment with pridopidine (6 mg/kg/day), or saline. Finally, novel objectrecognition performance was assessed in the animals. Mice receiving PCP andsaline exhibited deficits in novel object recognition, as expected, while pridopidinetreatment counteracted PCP-induced memory impairment. The effect of pridopidine wasattenuated by co-administration of the sigma receptor antagonist, NE-100 (10 mg/kg).Our results suggest that pridopidine exerts anti-amnesic and potentially neuroprotectiveactions. These data provide new insights into the therapeutic potential of pridopidine asa pro-cognitive drug.

Matèries

Malalties del sistema nerviós central, Dopamina, Assaigs clínics, Malalties neurodegeneratives

Matèries (anglès)

Central nervous system diseases, Dopamine, Clinical trials, Neurodegenerative Diseases

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

SAHLHOLM, Kristoffer, et al. Pridopidine Reverses Phencyclidine-Induced Memory Impairment. Frontiers in Pharmacology. 2018. Vol. 9, num. 338. ISSN 1663-9812. [consulted: 3 of August of 2026]. Available at: https://hdl.handle.net/2445/148123

Exportar metadades

JSON - METS

Compartir registre